These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 15051893)

  • 1. Melanoma cells transfected to express CD83 induce antitumor immunity that can be increased by also engaging CD137.
    Yang S; Yang Y; Raycraft J; Zhang H; Kanan S; Guo Y; Ronai Z; Hellstrom I; Hellstrom KE
    Proc Natl Acad Sci U S A; 2004 Apr; 101(14):4990-5. PubMed ID: 15051893
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antitumor efficacy of CD137 ligation is maximized by the use of a CD137 single-chain Fv-expressing whole-cell tumor vaccine compared with CD137-specific monoclonal antibody infusion.
    Zhang H; Knutson KL; Hellstrom KE; Disis ML; Hellstrom I
    Mol Cancer Ther; 2006 Jan; 5(1):149-55. PubMed ID: 16432173
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor cells expressing anti-CD137 scFv induce a tumor-destructive environment.
    Yang Y; Yang S; Ye Z; Jaffar J; Zhou Y; Cutter E; Lieber A; Hellström I; Hellström KE
    Cancer Res; 2007 Mar; 67(5):2339-44. PubMed ID: 17332366
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic vaccination with tumor cells that engage CD137.
    Hellstrom KE; Hellstrom I
    J Mol Med (Berl); 2003 Feb; 81(2):71-86. PubMed ID: 12601523
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gene therapy for cancer using single-chain Fv fragments specific for 4-1BB.
    Ye Z; Hellström I; Hayden-Ledbetter M; Dahlin A; Ledbetter JA; Hellström KE
    Nat Med; 2002 Apr; 8(4):343-8. PubMed ID: 11927939
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transgenic expression of a CD83-immunoglobulin fusion protein impairs the development of immune-competent CD4-positive T cells.
    Lüthje K; Cramer SO; Ehrlich S; Veit A; Steeg C; Fleischer B; Bonin Av; Breloer M
    Eur J Immunol; 2006 Aug; 36(8):2035-45. PubMed ID: 16841299
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NK and CD8+ T cell-mediated eradication of poorly immunogenic B16-F10 melanoma by the combined action of IL-12 gene therapy and 4-1BB costimulation.
    Xu D; Gu P; Pan PY; Li Q; Sato AI; Chen SH
    Int J Cancer; 2004 Apr; 109(4):499-506. PubMed ID: 14991570
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cutting edge: CD83 regulates the development of cellular immunity.
    Scholler N; Hayden-Ledbetter M; Dahlin A; Hellström I; Hellström KE; Ledbetter JA
    J Immunol; 2002 Mar; 168(6):2599-602. PubMed ID: 11884422
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Agonist anti-GITR antibody enhances vaccine-induced CD8(+) T-cell responses and tumor immunity.
    Cohen AD; Diab A; Perales MA; Wolchok JD; Rizzuto G; Merghoub T; Huggins D; Liu C; Turk MJ; Restifo NP; Sakaguchi S; Houghton AN
    Cancer Res; 2006 May; 66(9):4904-12. PubMed ID: 16651447
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 4-1BB-specific monoclonal antibody promotes the generation of tumor-specific immune responses by direct activation of CD8 T cells in a CD40-dependent manner.
    Miller RE; Jones J; Le T; Whitmore J; Boiani N; Gliniak B; Lynch DH
    J Immunol; 2002 Aug; 169(4):1792-800. PubMed ID: 12165501
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD83 is an I-type lectin adhesion receptor that binds monocytes and a subset of activated CD8+ T cells [corrected].
    Scholler N; Hayden-Ledbetter M; Hellström KE; Hellström I; Ledbetter JA
    J Immunol; 2001 Mar; 166(6):3865-72. PubMed ID: 11238630
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Costimulation of tumor-reactive CD4+ and CD8+ T lymphocytes by B7, a natural ligand for CD28, can be used to treat established mouse melanoma.
    Li Y; McGowan P; Hellström I; Hellström KE; Chen L
    J Immunol; 1994 Jul; 153(1):421-8. PubMed ID: 7515929
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunosuppressive human anti-CD83 monoclonal antibody depletion of activated dendritic cells in transplantation.
    Seldon TA; Pryor R; Palkova A; Jones ML; Verma ND; Findova M; Braet K; Sheng Y; Fan Y; Zhou EY; Marks JD; Munro T; Mahler SM; Barnard RT; Fromm PD; Silveira PA; Elgundi Z; Ju X; Clark GJ; Bradstock KF; Munster DJ; Hart DN
    Leukemia; 2016 Mar; 30(3):692-700. PubMed ID: 26286117
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of TGFbeta1 makes nonimmunogenic tumor cells effective for therapeutic vaccination.
    Liu P; Jaffar J; Zhou Y; Yang Y; Hellström I; Hellström KE
    J Immunother; 2009 Apr; 32(3):232-9. PubMed ID: 19242377
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regulation of follicular dendritic cell networks by activated T cells: the role of CD137 signaling.
    Sun Y; Blink SE; Chen JH; Fu YX
    J Immunol; 2005 Jul; 175(2):884-90. PubMed ID: 16002686
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-CD137 antibodies in the treatment of autoimmune disease and cancer.
    Mittler RS; Foell J; McCausland M; Strahotin S; Niu L; Bapat A; Hewes LB
    Immunol Res; 2004; 29(1-3):197-208. PubMed ID: 15181282
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stimulation of the glucocorticoid-induced TNF receptor family-related receptor on CD8 T cells induces protective and high-avidity T cell responses to tumor-specific antigens.
    Côté AL; Zhang P; O'Sullivan JA; Jacobs VL; Clemis CR; Sakaguchi S; Guevara-Patiño JA; Turk MJ
    J Immunol; 2011 Jan; 186(1):275-83. PubMed ID: 21106849
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rejection of K1735 murine melanoma in syngeneic hosts requires expression of MHC class I antigens and either class II antigens or IL-2.
    Chen PW; Ananthaswamy HN
    J Immunol; 1993 Jul; 151(1):244-55. PubMed ID: 8326126
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined CD137 (4-1BB) and adjuvant therapy generates a developing pool of peptide-specific CD8 memory T cells.
    Myers L; Lee SW; Rossi RJ; Lefrancois L; Kwon BS; Mittler RS; Croft M; Vella AT
    Int Immunol; 2006 Feb; 18(2):325-33. PubMed ID: 16373363
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-CD137 monoclonal antibody administration augments the antitumor efficacy of dendritic cell-based vaccines.
    Ito F; Li Q; Shreiner AB; Okuyama R; Jure-Kunkel MN; Teitz-Tennenbaum S; Chang AE
    Cancer Res; 2004 Nov; 64(22):8411-9. PubMed ID: 15548712
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.